Application
|
Oral administration of cordycepin (15 mg/kg per day) for 2 weeks significantly reduced the wet weight of the primary tumour lump, without any loss of bodyweight or systemic toxicity. Cordycepin (15 mg/kg per day) inhibited the tumour enlargement in the right thigh inoculated with B16-BL6 cells premixed with extracellular matrix. In hematogenic metastatic mouse model bearing B16-BL6 melanoma cells, 3-hour exposure to various concentrations of cordycepin (0.3, 1 and 3 μg/ml) dose-dependently reduced the number of nodules formed in lung at 15 days after the tumor injection. Cordycepin did not influence the growth curve of B16-BL6 cells at concentrations up to 3 μg/ml.
|
References:
[1]. Penman S, Rosbash M, Penman M. Messenger and heterogeneous nuclear RNA in HeLa cells: differential inhibition by cordycepin[J]. Proceedings of the National Academy of Sciences, 1970, 67(4): 1878-1885.
[2]. Kim H G, Shrestha B, Lim S Y, et al. Cordycepin inhibits lipopolysaccharide-induced inflammation by the suppression of NF-κB through Akt and p38 inhibition in RAW 264.7 macrophage cells[J]. European journal of pharmacology, 2006, 545(2): 192-199.
[3]. Yoshikawa N, Nakamura K, Yamaguchi Y, et al. Antitumour activity of cordycepin in mice[J]. Clinical and Experimental Pharmacology and Physiology, 2004, 31(s2).
[4]. Nakamura K, KONOHA K, YOSHIKAWA N, et al. Effect of cordycepin (3'-deoxyadenosine) on hematogenic lung metastatic model mice[J]. in vivo, 2005, 19(1): 137-141.
|